FDA advisers to weigh first psychedelic therapy in early June

Lykos Therapeutics’ MDMA-assisted therapy is charting yet another first in the psychedelic field: an FDA advisory meeting.

The biotech will meet with the Psychopharmacologic Drugs Advisory Committee on June 4, according to a late Monday release. This will be the first time that FDA experts will formally debate a psychedelic treatment. Lykos (formerly known as MAPS PBC) is seeking FDA approval to use MDMA to treat patients with post-traumatic stress disorder. The drug is commonly referred to as ecstasy.